Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › TYRA

Tyra Biosciences

TYRA Rare disease Lead: Phase 2 5 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $73.8M (Jun 30, 2026) ↓ 5 verdicts ↓ 2 timing quotes ↓
MetabolicOncology Small Molecule

Market cap $1.26B 59.7M shares (10-Q, Jul 31, 2026) × $21.15 close Nov 6, 2026

Most recent annual filing: 2026-03-02

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. BridgeBio infigratinib competitor NDA filing2H 2026BridgeBio infigratinib competitor NDA filing, 2H 2026, notable
  2. Dabogratinib readout2027Dabogratinib readout, 2027, notable
  3. BEACH301 ACH readoutlate 1Q 2027BEACH301 ACH readout, late 1Q 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

SNAP

Proprietary precision medicine platform enabling rapid and precise drug design through iterative molecular SNAPshots using protein crystallography, cell-based assays, and in vivo models. Applied to FGFR biology and other targets for oncology and rare/genetically defined conditions.

Targets: FGFR3, FGFR4, FGFR2, FGFR1, FGFR

Discontinued (1)

Capital (as filed)

Cash
$73.8M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$31.1M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$725M cash per the update of Sep 17, 2026 — the company's own words as read there, not the filed figure

Offering documents (4)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Tyra Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-11 Watch Tyra Biosciences (TYRA) — Scientific Deep Dive for Dabogratinib (TYRA-300) and the FGFR Pipeline Elite selective FGFR3 chemistry with a fortress balance sheet and blue-chip smart money, but fast-follower in ACH, J&J-dominated NMIBC field, doses covering IC50 not IC90, and zero Phase 2 efficacy in hand — revisit at the August IR NMIBC readout.
  2. 2026-08-05 Watch UPDATE: Tyra Biosciences (TYRA) - The Catalyst Slips Again, and the ATM Gets Reloaded Second catalyst slip and ACH readout delayed a full quarter, burn running hotter, and $250M ATM loaded above a stock already up 28% on no efficacy data — watch list maintained pending the September NMIBC print.
  3. 2026-09-09 Watch UPDATE: Tyra Biosciences (TYRA) - The 70% Bar, Missed by Thirteen Points 60 mg cohort missed the 70% CR bar at 57% but showed clean safety and a real dose-response curve pointing upward — thesis not broken but not validated, upgrade deferred to the 70 mg cohort and FDA Phase 3 design feedback.
  4. 2026-09-15 Watch UPDATE: Tyra Biosciences (TYRA) - The Faucet Opened, and the Stock Went Up $400M raise retires financing risk and pre-funded warrant structure signals specialist conviction, but substantial permanent dilution and an untouched $250M ATM remain overhead while the efficacy question awaits the 70 mg cohort.
  5. 2026-09-17 Watch UPDATE: Tyra Biosciences (TYRA) - RA Capital Bought Half the Raise RA Capital's $200M add and Paradigm's new 5.8% stake confirm specialist money read the 57% CR as a dosing problem not a drug failure, strengthening the ownership leg of the thesis, but efficacy at 70 mg remains the only thing that can convert the rating.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)